Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer
Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer: A Randomized Feasibility Study
Sponsor: Sunnybrook Health Sciences Centre
Listed as NCT04619069, this PHASE1/PHASE2 trial focuses on Prostate Cancer and remains ongoing. Sponsored by Sunnybrook Health Sciences Centre, it has been updated 6 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
May 2025 — Present [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Sep 2024 — May 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Jun 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 1 earlier version
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Oct 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sunnybrook Health Sciences Centre
For direct contact, visit the study record on ClinicalTrials.gov .